Russian Heart Failure Journal 2011year Comments to: "OCCH experts consensus. Results of SHIFT survey and recommendations to include Koraksan to the therapeutic regimen for CHF and sinus rhythm patients"


To access this material please log in or register

Register Authorize
2011/

Comments to: "OCCH experts consensus. Results of SHIFT survey and recommendations to include Koraksan to the therapeutic regimen for CHF and sinus rhythm patients"

Ageyev F. T.
Federal State Budgetary Institution, “Russian Cardiology Research and Production Complex” of the RF Ministry of Health Care, 3rd Cherepkovskaya 15a, Moscow 121552

Keywords:

DOI: 10.18087/ rhfj.2011.5.1571

  1. Согласованное мнение экспертов Общества специалистов по сердечной недостаточности. Результаты исследования SHIFT и рекомендации по включению Кораксана в схему лечения пациентов с ХСН и синусовым ритмом. Журнал Сердечная Недостаточность. 2011;12 (2):117–118.
  2. Swedberg K, Komajda M, Bohm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376 (9744):875–885.
  3. High heart rate: Culprit or bystander in heart failure? Аvailable at: http://www.theheart.org / article / 1229587.do
  4. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Журнал Сердечная Недостаточность. 2010;11 (1):3–62.
  5. CIBIS – II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet. 1999;353 (9146):9–13.
  6. MERIT-HF study group. Effect of metoprolol CR / XL in chronic heart failure: Metoprolol CR / XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353 (9169):2001–2007.
  7. Packer M, Bristow MR, Cohn JN et al, for the U. S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334 (21):1349–1355.
  8. de Groote P, Isnard R, Assyag P et al. Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey. Eur J Heart Fail. 2007;9 (12):1205–1211.
  9. Мареев В. Ю., Даниелян М. О. Оптимизация применения БЕталока ЗОК у больных ХСН в повседневной рабочей практикЕ. Дизайн и результаты исследования. Журнал Сердечная Недостаточность. 2005;6 (6):251–257.
  10. Результаты опроса врачей Западного округа г. Москвы. Доступно на: http://medic.ossn.ru / news / 11 / 2239 / 
Ageyev F.T. Comments to: "OCCH experts consensus. Results of SHIFT survey and recommendations to include Koraksan to the therapeutic regimen for CHF and sinus rhythm patients". Russian Heart Failure Journal. 2011;12(5):312-313.

To access this material please log in or register

Register Authorize
Ru En